Renal sympathetic denervation for treating resistant hypertension

Circulation Journal

Volumn 77, Issue 4, 2013, Pages 857-863

  Polimeni, Alberto ^a   Curcio, Antonio ^a   Indolf, Ciro ^a,b  

^a Laboratory of Molecular and Cellular Cardiology   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Endovascular therapy; Hypertension treatment; Renal denervation; Sympathetic nervous system; Systemic hypertension

Indexed keywords

ANGIOTENSIN II; COLLAGEN TYPE 1; COLLAGEN TYPE 3; NORADRENALIN; RENIN;

ARTERY DISSECTION; AUTONOMIC DENERVATION; DIASTOLIC BLOOD PRESSURE; FALSE ANEURYSM; HEMATOMA; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DENERVATION; MULTICENTER STUDY (TOPIC); NONHUMAN; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; REVIEW; SAFETY; SENSORY NERVE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VASOCONSTRICTION;

HUMANS; HYPERTENSION; KIDNEY; NERVE FIBERS; NEURONS, AFFERENT; NOREPINEPHRINE; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; SYNAPTIC TRANSMISSION;

EID: 84875486351     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0297     Document Type: Review

References (47)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 2013; 127: e6-e245.
2. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.
3. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 2010; 362: 590-599.
4. Noda K, Zhang B, Iwata A, Nishikawa H, Ogawa M, Nomiyama T, et al. Lifestyle changes through the use of delivered meals and dietary counseling in a single-blind study: The STYLIST study. Circ J 2012; 76: 1335-1344.
5. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: Diagnosis, evaluation, and treatment a scientific statement from the American Heart Association professional education committee of the Council for High Blood Pressure Research. Circulation 2008; 117: 510-526.
6. De Souza WA, Sabha M, de Faveri Favero F, Bergsten-Mendes G, Yugar-Toledo JC, Moreno HJ. Intensive monitoring of adherence to treatment helps to identify "true" resistant hypertension. Clin Hypertens 2009; 11: 183-191.
7. Dworkin LD, Cooper CJ. Clinical practice. Renal-artery stenosis. N Engl J Med 2009; 361: 1972-1978.
8. Chiong JR, Aronow WS, Khan IA, Nair CK, Vijayaraghavan K, Dart RA, et al. Secondary hypertension: Current diagnosis and treatment. Int J Cardiol 2008; 124: 6-21.
9. Parati G, Esler M. The human sympathetic nervous system: Its relevance in hypertension and heart failure. Eur Heart J 2012; 33: 1058-1066.
10. Osborn JL, DiBona GF, Thames MD. Beta-1 receptor mediation of renin secretion elicited by low-frequency renal nerve stimulation. J Pharmacol Exp Ther 1981; 216: 265-269.
11. Makaritsis KP, Johns C, Gavras I, Gavras H. Role of alpha(2)-adrenergic receptor subtypes in the acute hypertensive response to hypertonic saline infusion in anephric mice. Hypertension 2000; 35: 609-613.
12. Passmore JC, Joshua IG, Rowell PP, Tyagi SC, Falcone JC. Reduced alpha adrenergic mediated contraction of renal preglomerular blood vessels as a function of gender and aging. J Cell Biochem 2005; 96: 672-681.
13. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009; 54: 1747-1762.
14. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108: 560-565.
15. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14: 425-430.
16. Indolfi C, Maione A, Volpe M, Rapacciuolo A, Esposito G, Ceravolo R, et al. Forearm vascular responsiveness to alpha 1-and alpha 2-adrenoceptor stimulation in patients with congestive heart failure. Circulation 1994; 90: 17-22.
17. Indolfi C, Piscione F, Villari B, Russolillo E, Rendina V, Golino P, et al. Role of alpha 2-adrenoceptors in normal and atherosclerotic human coronary circulation. Circulation 1992; 86: 1116-1124.
18. Indolfi C, Piscione F, Ceravolo R, Maione A, Focaccio A, Rao MA, et al. Limb vasoconstriction after successful angioplasty of the left anterior descending coronary artery. Circulation 1995; 92: 2109-2112.
19. Quinby WC, Dexter L, Sandmeyer JA, Haynes FW. The renal humoral pressor mechanism in man. II: The effect of transitory complete constriction of the human renal artery on blood pressure and on the concentration of renin, hypertensinogen, and hypertensinase of renal arterial and venous blood, with animal observations. J Clin Invest 1945; 24: 69-74.
20. Longland CJ, Gibb WE. Sympathectomy in the treatment of benign and malignant hypertension; a review of 76 patients. Br J Surg 1954; 41: 382-392.
21. Smit AA, Timmers HJ, Wieling W, Wagenaar M, Marres HA, Lenders JW, et al. Long-term effects of carotid sinus denervation on arterial blood pressure in humans. Circulation 2002; 105: 1329-1335.
22. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-934.
23. Krum H, Schlaich M, Whitburn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281.
24. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917.
25. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): A randomised controlled trial. Lancet 2010; 376: 1903-1909.
26. Kottke FJ, Kubicek WG, Visscher MB. The production of arterial hypertension by chronic renal artery-nerve stimulation. Am J Physiol 1945; 145: 38-47.
27. Porlier GA, Nadeau RA, De Champlain J, Bichet DG. Increased circulating plasma catecholamines and plasma renin activity in dogs after chemical sympathectomy with 6-hydroxydopamine. Can J Physiol Pharmacol 1977; 55: 724-733.
28. O'Hagan KP, Thomas GD, Zambraski EJ. Renal denervation decreases blood pressure in DOCA-treated miniature swine with established hypertension. Am J Hypertens 1990; 3: 62-64.
29. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995; 25: 893-897.
30. Abramczyk P, Zwoliñska A, Oficjalski P, Przybylski J. Kidney denervation combined with elimination of adrenal-renal portal circulation prevents the development of hypertension in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1999; 26: 32-34.
31. Nozawa T, Igawa A, Fujii N, Kato B, Yoshida N, Asanoi H, et al. Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats. Heart Vessels 2002; 16: 51-56.
32. Alexander BT, Hendon AE, Ferril G, Dwyer TM. Renal denervation abolishes hypertension in low-birth-weight offspring from pregnant rats with reduced uterine perfusion. Hypertension 2005; 45: 754-758.
33. Salman IM, Sattar MA, Ameer OZ, Abdullah NA, Yam MF, Salman HM, et al. Role of norepinephrine and angiotensin II in the neural control of renal sodium and water handling in spontaneously hypertensive rats. Indian J Med Res 2010; 131: 786-792.
34. Rippy MK, Zarins D, Barman NC, Wu A, Duncan KL, Zarins CK. Catheter-based renal sympathetic denervation: Chronic preclinical evidence for renal artery safety. Clin Res Cardiol 2011; 100: 1095-1101.
35. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, et al. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 2012; 125: 1402-1413.
36. Page IH, Heuer GJ. A surgical treatment of essential hypertension. J Clin Invest 1935; 14: 22-26.
37. Grimson KS, Orgain ES, Anderson B, D'Angelo GJ. Total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy for hypertension. Ann Surg 1953; 138: 532-547.
38. Peet MM. Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy. Am J Surg 1948; 75: 48-68.
39. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1266 cases. JAMA 1953; 152: 1501-1504.
40. Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation and systemic hypertension. Am J Cardiol 2010; 105: 570-576.
41. VA Trial. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967; 202: 1028-1034.
42. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: One-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 2012; 126: 2976-2982.
43. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, et al. Catheter-based renal denervation for resistant hypertension: Rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012; 35: 528-535.
44. Matsui K, Kamijo-Ikemori A, Sugaya T, Yasuda T, Kimura K. Usefulness of urinary biomarkers in early detection of acute kidney injury after cardiac surgery in adults. Circ J 2012; 76: 213-220.
45. Tajiri K, Maruyama H, Sato A, Shimojo N, Saito T, Endo M, et al. Prediction of chronic renal insufficiency after coronary angiography by an early increase in oxidative stress and decrease in glomerular filtration rate. Circ J 2011; 75: 437-442.
46. Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: Approach to therapy. Circ J 2011; 75: 1287-1296.
47. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-909.